Zentalis Pharmaceuticals Statistics
Total Valuation
ZNTL has a market cap or net worth of $198.81 million. The enterprise value is $61.89 million.
| Market Cap | 198.81M |
| Enterprise Value | 61.89M |
Important Dates
The next estimated earnings date is Monday, November 9, 2026, after market close.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ZNTL has 94.67 million shares outstanding. The number of shares has decreased by -0.23% in one year.
| Current Share Class | 94.67M |
| Shares Outstanding | 94.67M |
| Shares Change (YoY) | -0.23% |
| Shares Change (QoQ) | +1.51% |
| Owned by Insiders (%) | 2.12% |
| Owned by Institutions (%) | 50.69% |
| Float | 74.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 169.85 |
| PB Ratio | 1.06 |
| P/TBV Ratio | 1.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.26.
| Current Ratio | 4.82 |
| Quick Ratio | 4.64 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -66.75% and return on invested capital (ROIC) is -37.81%.
| Return on Equity (ROE) | -66.75% |
| Return on Assets (ROA) | -33.15% |
| Return on Invested Capital (ROIC) | -37.81% |
| Return on Capital Employed (ROCE) | -84.63% |
| Weighted Average Cost of Capital (WACC) | 12.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.32M |
| Employee Count | 106 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ZNTL has paid $700,000 in taxes.
| Income Tax | 700,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +33.96% in the last 52 weeks. The beta is 1.94, so ZNTL's price volatility has been higher than the market average.
| Beta (5Y) | 1.94 |
| 52-Week Price Change | +33.96% |
| 50-Day Moving Average | 3.30 |
| 200-Day Moving Average | 3.47 |
| Relative Strength Index (RSI) | 26.82 |
| Average Volume (20 Days) | 1,369,449 |
Short Selling Information
The latest short interest is 5.96 million, so 6.29% of the outstanding shares have been sold short.
| Short Interest | 5.96M |
| Short Previous Month | 4.79M |
| Short % of Shares Out | 6.29% |
| Short % of Float | 7.96% |
| Short Ratio (days to cover) | 5.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -150.39M |
| Pretax Income | -138.85M |
| Net Income | -139.55M |
| EBITDA | -149.77M |
| EBIT | -150.39M |
| Earnings Per Share (EPS) | -$1.96 |
Balance Sheet
The company has $174.61 million in cash and $37.69 million in debt, with a net cash position of $136.92 million or $1.45 per share.
| Cash & Cash Equivalents | 174.61M |
| Total Debt | 37.69M |
| Net Cash | 136.92M |
| Net Cash Per Share | $1.45 |
| Equity (Book Value) | 143.65M |
| Book Value Per Share | 2.00 |
| Working Capital | 143.65M |
Cash Flow
In the last 12 months, operating cash flow was -$128.10 million and capital expenditures -$34,000, giving a free cash flow of -$128.13 million.
| Operating Cash Flow | -128.10M |
| Capital Expenditures | -34,000 |
| Depreciation & Amortization | 621,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -128.13M |
| FCF Per Share | -$1.35 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ZNTL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.23% |
| Shareholder Yield | 0.23% |
| Earnings Yield | -69.20% |
| FCF Yield | -63.54% |
Analyst Forecast
The average price target for ZNTL is $7.44, which is 254.29% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.44 |
| Price Target Difference | 254.29% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |